Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.05 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
GBS Inc had its IPO on 2020-12-23 under the ticker symbol GBS.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. GBS Inc has a staff strength of 12 employees.
Shares of GBS Inc opened at $1.29 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of $1.07 - $1.44, and closed at $1.19.
This is a +15.53% increase from the previous day's closing price.
A total volume of 30,240,829 shares were traded at the close of the day’s session.
In the last one week, shares of GBS Inc have increased by +325.46%.
GBS Inc's Key Ratios
GBS Inc has a market cap of $7.05 million, indicating a price to book ratio of 1.1803 and a price to sales ratio of 16.118.
In the last 12-months GBS Inc’s revenue was $437146 with a gross profit of $437146 and an EBITDA of $0. The EBITDA ratio measures GBS Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, GBS Inc’s operating margin was -1907.12% while its return on assets stood at -30.46% with a return of equity of -77.34%.
In Q3, GBS Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.8%.
GBS Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.502 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into GBS Inc’s profitability.
GBS Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.9131. Its price to sales ratio in the trailing 12-months stood at 16.118.
GBS Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.16 million
- Total Liabilities
- $2.36 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
GBS Inc ended 2023 with $10.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.16 million while shareholder equity stood at $5.28 million.
GBS Inc ended 2023 with $0 in deferred long-term liabilities, $2.36 million in other current liabilities, 148899.00 in common stock, $-32384146.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.74 million and cash and short-term investments were $5.74 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
GBS Inc’s total current assets stands at $8.21 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.08 million compared to accounts payable of $379912.00 and inventory worth $0.
In 2023, GBS Inc's operating cash flow was $0 while its capital expenditure stood at $474891.
Comparatively, GBS Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
GBS Inc stock is currently trading at $1.19 per share. It touched a 52-week high of $1.44 and a 52-week low of $1.44. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.35 and 200-day moving average was $0.55 The short ratio stood at 1.84 indicating a short percent outstanding of 0%.
Around 905.1% of the company’s stock are held by insiders while 278.8% are held by institutions.
Frequently Asked Questions About GBS Inc
Similar Industry Stocks (Biotechnology & Medical Research)
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.